Revumenib (brand name Revuforj) is a first-in-class, oral menin inhibitor used to treat specific types of aggressive acute leukemia.
It is specifically [FDA-approved for relapsed-or-refractory-acute-leukemia-with kmt2a-translocation for adult and pediatric patients 1 year and older.
* A KMT2A rearrangement (translocation). * A susceptible NPM1 mutation.
Revumenib works by blocking the interaction between the menin protein and MLL1 fusion proteins, which helps stop the growth of leukemia cells.
In pivotal trials, it demonstrated a complete remission (CR) or CR with partial hematological recovery (CRh) rate of approximately 23% in heavily pre-treated patients.
Safety and Side Effects
Differentiation Syndrome: A potentially fatal condition where the rapid release of cytokines causes symptoms like fever, cough, and rapid weight gain.
QTc Prolongation: Changes in the heart’s electrical activity that can lead to irregular heartbeats.
Patients require baseline and regular EKG monitoring.
Common Reactions: Other frequent side effects include nausea, musculoskeletal pain, infection, febrile neutropenia, and increased liver enzymes.